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Abstract
Background: Lactic acidosis (LA) is a complication of diseases commonly seen in intensive care patients which carries 
an increased risk of mortality. It is classified by its pathophysiology; Type A results from tissue hypo-perfusion and 
hypoxia, and Type B results from abnormal metabolic activity in the absence of hypoxia. Reports of the co-occurrence 
of both types have been rarely reported in the literature relating to intensive care patients. This case report describes 
the challenging management of a patient diagnosed with both Type A and Type B LA.
Case presentation: A 55-year-old female with newly diagnosed diffuse large B-cell lymphoma (DLBCL) developed 
hospital-acquired pneumonia, respiratory failure, shock and intra-abdominal septicaemia from a bowel perforation. 
Blood gases revealed a mixed picture lactic acidosis. Correction of septic shock, respiratory failure and surgical repair 
caused initial improvement to the lactic acidosis, but this gradually worsened in the intensive care unit. Only upon 
starting chemotherapy and renal replacement therapy was full resolution of the lactic acidosis achieved. The patient 
was discharged but succumbed to her DLBCL several months later. 
Conclusion: Type A and Type B LA can co-occur, making management difficult.  A systematic approach can help diag-
nose any underlying pathology and aid in early management.
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 Background
An underlying disease may cause lactic acidosis (LA), 
and its presence is associated with an increased risk of 
mortality [1]. It is a common cause of raised anion gap 
acidosis in intensive care patients, though it can exist 
with a normal anion gap [2]. In the latter situation, ac-
curate diagnosis can be difficult. Historically, a serum 
pH < 7.35 and lactate > 5mmol/L was a widely accepted 
definition of lactic acidosis [3], however reports in re-
cent literature suggest that overt hyperlactatemia and 
acidosis are not always apparent in LA [4]. A specific 
universal definition remains elusive because of varia-
tions in cut-off limits between clinical laboratories [4]. 
Nonetheless, an essential diagnostic criterion is hyper-
lactatemia or an increase in serum lactate from base-
line albeit still within the normal range. A pH < 7.35 
may not always be present in LA because respiratory 
compensation and alkalosis may occur [4].
LA can be classified into two types based on their 
pathophysiology; Type A and Type B [4]. Type A LA 
results from hypoperfusion and tissue hypoxia in con-
ditions such as sepsis, shock, hypovolemia or severe 
hypoxia, whereas Type B LA results from an imbalance 
of normal physiological metabolism [4] caused by an 
underlying disease, drugs or toxins and inborn errors 
of metabolism. Type B LA can be sub-divided further 
as Type B1 (disease-associated), Type B2 (drug or toxin 
associated) and Type B3 (inborn metabolic errors) re-
spectively. At a cellular level, disease mechanisms can 
differ between the types of LA, e.g. anaerobic respira-
tion versus the Warburg effect in normoxia. Having 
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Type A and Type B LA simultaneously is physiologi-
cally possible, although rarely reported in the literature 
relating to intensive care patients.
This case report describes a challenging case of re-
fractory lactic acidosis arising from respiratory failure, 
intra-abdominal sepsis and diffuse large B-cell lym-
phoma (DLBCL) mimicking the features of ischaemic 
bowel. Subsequently, a recommended structured ap-
proach to aid in the diagnosis of its underlying cause(s) 
in difficult or complicated cases is outlined.
 Case Presentation
A 55-year-old female was transferred to the oncology 
centre for tertiary care.  She had a two-week history 
of abdominal distension and a past medical history of 
ovarian cancer for which she had had a hysterectomy, bi-
lateral salpingo-oophorectomy and five cycles of chem-
otherapy more than ten years ago. She was not on any 
regular medication. Blood tests demonstrated a normo-
chromic normocytic anaemia, healthy liver and kidney 
function as well as normal clotting limits. Imaging in-
cluding computerised tomography (CT) with contrast, 
revealed significant ascites, a moderate right pleural ef-
fusion, a 10cm x 8cm x 2.8cm pelvic mass at the distal 
ileum and normal liver parenchyma. Cytology from a 
pleuritic tap demonstrated diffuse large B cell lymphoma 
(DLBCL), consistent with biopsy results from the pelvic 
mass. The pleural effusion and ascites were then drained 
successfully without any complications.
One week after her admission, the patient developed 
a persistent tachycardia and respiratory failure requir-
ing intubation and ventilation in the Intensive Care 
Unit (ICU). Arterial blood gases revealed metabolic 
acidosis with respiratory compensation  (pH 7.29, CO2 
29mmHg, pO2 77mmHg on 0.5 FiO2, BE -11.7 HCO3- 
13mmol/L and lactate 5.7mmol/L). The anion gap was 
mildly elevated at 18 (normal range 8-16mEq/L). A 
chest X-ray (CXR) performed post-intubation dem-
onstrated pneumoperitoneum and left lower zone lung 
consolidation (Figure 1). 
An emergency exploratory laparotomy was per-
formed without further imaging as the clinical diagno-
sis was septic shock secondary to perforated gut. More-
over, the patient was progressively drowsy, tachycardic 
(heart rate 170 beats/min) and hypotensive (blood pres-
sure 82/50 mmHg. Pre-operatively, 500ml fluid bolus-
es were given, increasing the blood pressure to 90/60 
mmHg after a total of two litres given. Noradrenaline 
(Pfizer Ltd) infusion was started intra-operatively 
and titrated to a maximum dose of 0.1mcg/kg/min to 
achieve a mean arterial pressure of 65mmHg. Intra-
operative findings confirmed the presence of a pelvic 
lymphoma, with involvement and perforation of the 
distal ileum causing feculent peritonitis. The perforat-
ed and diseased segment of bowel was resected. Tem-
porary abdominal closure was done given the extensive 
soilage and oedematous small bowel loops with a view 
for a relook laparotomy and double barrel stoma in the 
next two days. Broad-spectrum empirical antibiotics 
consisting of Vancomycin (Pfizer Ltd) 1gm 12 hourly, 
Caspofungin (Merck Sharp & Dohme Ltd) 50mg 24 
hourly and Meropenem (Pfizer Ltd) 1gm 8 hourly were 
started intravenously in view of the extensive feculent 
peritonitis and hospital-acquired pneumonia causing 
septic shock.
Postoperatively, the patient returned to the ICU and 
a Fentanyl (AAH Pharmaceuticals Ltd) infusion was 
started for postoperative analgesia. The Noradrenaline 
infusion which was started intra-operatively at a dose 
of 0.1mcg/kg/min, was subsequently weaned off within 
24hours. Despite achieving a mean arterial blood pres-
sure target of greater than 65mmHg, a urine output 
of 0.5-1ml/kg/hr with 2 litres of PlasmaLyte (Baxter 
Healthcare Ltd) infusion, 20% human albumin solu-
tion (Octapharma Ltd) 100ml 24 hourly and being in 
positive fluid balance, her tachycardia and lactic acido-
sis did not improve (see Figure 2). 
A left shift neutrophilia was noted, but her liver 
function tests and renal function tests remained nor-
 Fig. 1. CXR showing the presence of pneumoperitoneum, 
left sided consolidation and a right sided chest drain from 
an earlier insertion for a moderate right sided pleural 
effusion
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mal. After four days in the ICU, the patient’s respira-
tory failure resolved, and the hyperlactatemia pla-
teaued briefly. It was then clear that Type A LA was 
only contributory to the ongoing lactic acidosis and 
not the predominant factor. Type B LA from intra-
abdominal sepsis was then attributed to the ongoing 
hyperlactatemia as Klebsiella pneumoniae, and Can-
dida  tropicalis were isolated from her blood cultures. 
The intravenous Meropenem was promptly changed to 
intravenous Ceftazidime-Avibactam (Pfizer Ltd) 2.5gm 
8 hourly because the isolated Klebsiella pneumoniae 
was found to be Meropenem-resistant. A respiratory 
wean was attempted, but this was prolonged because 
of severe tachypnoea - the patient having a sponta-
neous respiratory rate of 35 to 45 breaths per minute 
despite adequate tidal volumes generated on pressure 
support ventilation. This was attributed to respiratory 
compensation from the lactic acidosis as other causes 
of tachypnoea such as pain, pulmonary embolism and 
hypoxia were excluded.  A review of the patient’s in-
patient medications at this point revealed she was on 
intravenous Vancomycin 1gm 12 hourly, Caspofungin 
50mg 24 hourly and Ceftazidime Avibactam 2.5gm 8 
hourly and a Fentanyl infusion at a rate of 10-50mcg/hr. 
No apparent pharmacological cause for the hyperlac-
tatemia was identified and these medications were giv-
en for a total of 10 days.
Due to worsening of the Type B LA, a second lapa-
rotomy was performed to rule out bowel ischemia or 
loculated collections given her initial presentation 
with bowel perforation, feculent peritonitis and sep-
tic shock. However, no abnormalities were found, and 
the intra-abdominal pressure was noted to be normal 
(12mmHg). A double barrel stoma was created, and 
permanent abdominal closure was undertaken. Daily 
blood investigations done during her stay in the In-
tensive Care Unit included full blood count, C Reac-
tive protein, procalcitonin, renal panel, liver function 
test, serum calcium, phosphate and magnesium levels. 
In addition, echocardiography and chest X-rays were 
done as clinically indicated. Over time, the biomark-
ers of infection (white blood cell count, C-reactive 
protein and procalcitonin) demonstrated a downward 
trend. After further discussion between the intensiv-
ists, general surgeons and oncologists, a serum lac-
tate dehydrogenase (LDH) was performed, and it was 
found to be elevated at 1002 units/L, suggesting high 
DLBCL activity. With all other causes of LA addressed, 
 Fig. 2. Trend of serum lactate, total white blood cell count and heart rate (Day 1 = first day of admission to ICU).
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the worsening Type B LA was attributed to the DLBCL. 
Continuous renal replacement therapy (CRRT) was 
commenced to help with the clearance of lactate. Cy-
clophosphamide, rituximab and etoposide were started 
as chemotherapy, and complete resolution of the Type 
B LA was noted one week after. The patient was extu-
bated and transferred out of the ICU 2 weeks after ICU 
admission but unfortunately succumbed to her DLBCL 
several months later.
 Discussion 
This patient suffered from Type A and Type B1 LA. 
Only after weaning off cardio-respiratory support and 
treating the sepsis did it became apparent that the pre-
dominant cause of the patient’s lactic acidosis was DL-
CBL. Interestingly, with the bulk of the disease local-
ised in the pelvis, together with the downward trends 
of both CRP and PCT, an aggressively and rapidly 
progressing DLBCL was not initially suspected as the 
most likely cause of lactic acidosis. Later, the high LDH 
level and resolution of the other causes of Type B LA 
were the factors that prompted the commencement of 
chemotherapy.
LDH, an intracellular enzyme which catalyses the 
conversion of lactate to pyruvate and vice versa,  is 
an established biomarker for disease activity in non-
Hodgkin’s lymphoma[5]. However, it is noteworthy 
that five isoforms of the enzyme exist and these are dis-
tributed differently in the organs of the human body 
[6]. Therefore, there can be many causes of an elevated 
LDH and determining the sub-type of LDH improves 
the diagnostic specificity. It is also noteworthy that 
elevated LDH levels are not directly linked to hyper-
lactatemia or LA although both signify an underlying 
pathology.
Lactate exists in two isomers, L-Lactate and D-Lac-
tate. L-lactate is produced by most tissues in the human 
body and is used as standard measurements in clinical 
practice. D-lactate is produced by bacteria in the large 
bowel and diseases such as short bowel syndrome can 
increase serum D-lactate levels. 
Concerning this case, the discussion has been limit-
ed to L-lactate. Under anaerobic conditions, L-lactate is 
an end product of glycolysis cycle and is used as a sub-
strate for gluconeogenesis. Therefore, in tissue hypop-
erfusion and hypoxia, cellular lactate production is in-
creased, and this results in hyperlactatemia. However, 
cellular lactate production can be increased by different 
mechanisms in the absence of hypoxia. For example, 
many malignancies, not limited to DLBCL, have been 
associated with hyperlactatemia through what has 
been termed the “Warburg effect” [7]. The Warburg ef-
fect describes the propensity of cancer cells to convert 
incoming glucose to lactate in aerobic respiration pref-
erentially [8]. Though its mechanisms were previously 
poorly understood, recent research has demonstrated 
that in cancer cells, aberrant changes to genes Myc, 
Ras, Akt and p53, lead to the over-expression of gly-
colytic enzymes and glucose transporters thus result-
ing in increased cellular lactate production [9-18]. This 
strategic use of lactate as an energy source contributes 
to the survival of rapidly dividing cancer cells.
The monitoring of serum lactate undoubtedly pro-
vides essential information regarding the diagnosis of 
disease as well as the response to treatment in critically 
ill patients. However, there is an ongoing debate as to 
whether arterial or venous sampling should be used. A 
PubMed literature search using the search terms “sys-
tematic review”, “arterial”, “venous” and “lactate” re-
vealed only two systematic reviews and meta-analyses 
directly comparing the two methods.
Kruse et al. (2001) concluded that arterial lactate 
sampling is the gold standard, but venous sampling 
also is advantageous in detecting hyperlactatemia and 
therefore should be used as a screening tool. However, 
they acknowledged that venous sampling was associ-
ated with higher lactate values compared to arterial val-
ues and that a universal cut-off value could not be es-
tablished reliably by the study [19]. Bloom et al. (2014) 
concluded that peripheral venous sampling has a good 
correlation to arterial sampling within “normal” rang-
es, but a poor agreement exists between arterial and 
venous lactate at abnormal values [20]. It is opined that 
although peripheral venous sampling is an acceptable 
method of screening for hyperlactatemia, arterial or 
central venous lactate [21] is better suited for diagnos-
ing and monitoring the disease. 
We also agree with Kraut and Madias [4] that univer-
sal parameters and consensus to define lactic acidosis 
are lacking [22], and it is likely that the issues discussed 
by Kruse et al. (2001) and Bloom et al. (2014) have con-
tributed to this. Thus, there is ambiguity in the distinc-
tions between lactic acidosis and hyperlactatemia since 
lactic acidosis can be present with a normal pH and 
the serological values of lactate cannot be used strictly 
to distinguish the two. Setting clinical definitions aside, 
hyperlactatemia and lactic acidosis are, physiologically, 
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two ends of a spectrum where excessive lactate caus-
es acidosis as the underlying aetiology worsens. It is, 
therefore, reasonable to view hyperlactatemia and lac-
tic acidosis as a single entity in clinical practice since 
definitions are not robust and do not alter management 
significantly.  
In summary, the downward trend and resolution 
of hyperlactatemia remain important in goal-directed 
therapy since elevated levels are associated with in-
creased mortality [23, 24] — the correction of hyper-
lactatemia hinges on the treatment of the underlying 
cause. Vasopressors, fluid replacement or mechanical 
ventilation can help improve Type A LA whereas the 
treatment of Type B LA can prove more challenging. 
Intravenous bicarbonate and hemodialysis both have 
been used to control lactic acidosis as bridging thera-
pies while allowing time for ongoing treatment such as 
chemotherapy to take effect in this case. Adverse effects 
of intravenous bicarbonate treatment include hyperna-
tremia and hypervolaemia, and clinicians must be vigi-
lant for these. Renal replacement therapies, both in the 
form of peritoneal dialysis and hemofiltration have also 
been widely used for lactate clearance and the correc-
tion of associated metabolic acidosis. 
 Conclusion
Type A and Type B LA can co-occur. Diagnosing the 
cause of LA in critically ill patients can be challenging 
in complex cases, and the monitoring of lactate can be 
a valuable marker of disease activity or treatment re-
sponse. Viewing hyperlactatemia and lactic acidosis as 
a single clinical entity, adopting a structured approach 
and early multi-disciplinary input can improve clinical 
management and patient outcomes.
We propose a structured approach to aid clinicians 
in the early management of hyperlactatemia and LA in 
Annex 1.
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Type A Lactic Acidosis - associated with tissue hypoperfusion and hypoxia (quickly correctable)  
o Optimize oxygen delivery  
▪ Increase arterial oxygen saturation to > 92% unless contraindicated  
▪ Increase haemoglobin to > 7g/dL (>10gdL with cardiac disease)  
▪ Address increased oxygen demand (fever, pain, agitation) 
o Evaluate for global hypoperfusion  
▪ Clinical signs: Skin mottling, capillary refill time  
▪ Correct shock based on aetiology (distributive, cardiogenic, etc)  
o Evaluate for local tissue hypoperfusion  
▪ Mesenteric or limb ischemia, compartment syndrome, burns, trauma  
Causes of Type A Lactic Acidosis  Screening investigations  
Anaerobic muscle activity e.g. generalised 
convulsions, sports (intensive exercise)  
No specific tests - history and examination elucidates cause  
Shock, cardiac arrest  Echocardiography, mixed central venous oxygen saturation (ScVO2), 
CO2 gap, oxygen challenge test, peripheral perfusion index (PPI), tissue 
oxygen saturation, sublingual microcirculation microscopy.  
Burns and trauma  History and examination (CT imaging if trauma)  
Regional hypoperfusion  Ischaemic bowel: Mesenteric CT angiography  
Ischaemic limb: Examination, Dopplers  
Regional tissue oxygen saturation (near-infrared spectroscopy; NIRS)  
Hypoxaemia  Arterial blood gases (ABG), pulse oximetry  
Severe anaemia  Full blood count  
CO poisoning  ABG, venous carboxyhaemoglobin, co-oximetry  
Check for Type B Lactic Acidosis - associated with imbalance of metabolism due to underlying disease and drugs (longer term correction usually 
needed).  
o Type B1 lactic acidosis: Investigate for underlying disease/  
o Type B2 lactic acidosis: Stop potential causative medications/drugs.  
o Type B3 lactic acidosis: Consider inborn errors of metabolism.   
Causes of Type B1 Lactic Acidosis:  
(Type B1 - Disease associated)  
Screening investigations including history and examination:  
Malignancy  CT imaging of chest/abdomen/pelvis ± neck  
Thiamine deficiency  Diagnosis mainly from history and examination - high suspicion if malignancy, malnutrition or chronic 
alcohol. Erythrocyte thiamine pyrophosphate if available.  
Phaeochromocytoma  Serum metanephrines and urine catecholamines  
Diabetic Ketoacidosis  Blood sugars, arterial blood gas, blood ketones  
Short gut syndrome  History and examination  
Pancreatitis  Amylase, CT Pancreas  
Tumour Lysis Syndrome  Serum uric acid, phosphate, calcium, potassium  
Polymyositis  Creatine kinase, aldolase, liver function tests, CRP, ESR, electromyography  
Sepsis, infection  Full blood count, CRP and/or procalcitonin  
Liver failure  Liver function tests, clotting studies  
Renal failure  Renal function tests, urine output measurements   
Causes of Type B2 Lactic Acidosis:  
(Type B2 - Drug or toxin related)  
Check for:  
Medications  Metformin, phenformin, valproate, theophylline, propofol, isoniazid, salicylates, α-agonists, linezolid, 
epinephrine, propylene glycol, fialuridine, nucleoside reverse transcriptase inhibitors (NRTIs), 
paracetamol, lactate-based dialysates  
Toxins  Cyanide poisoning: Clinical diagnosis in acute setting. Cyanide levels used to confirm diagnosis.   
Alcohol poisoning: serum alcohol   
Causes of Type B3 Lactic Acidosis:  
(Type B3 - Inborn errors of metabolism)  
Pyruvate carboxylase deficiency, pyruvate dehydrogenase deficiency, mitochondrial 
encephalomyopathy and stroke-like episodes (MELAS), GRACILE syndrome, glucose-6 phosphatase 
deficiency (G6PD), fructose 1,6-bisphosphatase deficiency, biotinidase deficiency, multiple carboxylase 
deficiency  
 
Rising trend in serum lactate ± acid-base imbalance 
Check for Type A lactic acidosis and treat accordingly 
Continue 
treatment 
and 
monitor 
Improvement 
No improvement and no 
evidence of hypoperfusion 
and hypoxia  
 
Check for Type B Lactic Acidosis and treat accordingly 
Continue treatment 
and monitor 
 
Check D-lactate levels if 
other causes are not found 
and gastro-intestinal 
disease present  
 
Improvement 
No 
Improvement 
Annex 1. A structured approach to hyperlactatemia and lactic acidosis 
